Regenxbio plunges as FDA places hold on Hunter syndrome gene therapy
BUZZ-Regenxbio plunges as FDA places hold on Hunter syndrome gene therapy Updates
** Shares of drug developer Regenxbio RGNX.O tumble 24.4% to a three-month low of $8.08
** Stock is on track for its biggest one-day percentage drop since May, if losses hold
** The U.S. FDA places a clinical hold on Regenxbio's experimental gene therapy RGX-121 for Hunter syndrome after MRI scans identify small, symptom-free spinal abnormalities in five patients
** All five patients remain clinically stable or show improvement, and doctors believe the findings are likely benign - company
** RGNX does not expect to resubmit its U.S. approval application for RGX-121 in the near term
** Earlier this year, the FDA had declined to approve RGX-121, citing uncertainty regarding the trial design
** Including session moves, stock down 44% YTD
(Reporting by Kamal Choudhury and Siddhi Mahatole in Bengaluru)
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics